Non-viral delivery gene editing takes an important step forward for Angelman syndrome
A FAST-funded study unveils STEP-RNP, a non-viral gene editing platform showing improved motor, cognitive function in AS mice—an early but promising step toward treating Angelman syndrome.
Update on Rugonersen Development and Planned Phase 3 Study (BEACON)
Oak Hill Bio shared an update on rugonersen’s development, preparing to launch its Phase 3 study in mid-2026. Eligibility details are now available on clinicaltrials.gov.